Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils-Reference-Cited by-同舟云学术

Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils

Published:1998-06 Issue:3 Volume:124 Page:547-555
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

Anderson R,Mahomed A Goolam,Theron A J,Ramafi G,Feldman C

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/sj.bjp.0701849/fullpdf

Reference34 articles.

1. Cyclic AMP-increasing agents interfere with chemoattractantinduced respiratory burst in neutrophils as a result of the inhibition of phosphatidyl-inositol 3-kinase rather than receptor-operated Ca2+-influx;Ahmed;J. Biol. Chem.,1995

2. Anti-inflammatory, membranestabilizing interactions of salmeterol with human neutrophils in vitro;Anderson;Br. J. Pharmacol.,1996

3. In vitro stimulation of neutrophil motility by levamisole. Maintenance of cGMP levels in chemotactically stimulated human neutrophils;Anderson;J. Immunol.,1976

4. Calcium efflux and influx in FMLP-activated human neutrophils are chronologically distinct events;Anderson;Clin. Exp. Immunol.,1997

5. Theophylline in the management of asthma: time for reappraisal?;Barnes;Eur. Resp. J.,1994

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostaglandin E2inhibits neutrophil extracellular trap formation through production of cyclic AMP;British Journal of Pharmacology;2015-12-16

2. Warifteine, an Alkaloid Purified fromCissampelos sympodialis, Inhibits Neutrophil MigrationIn VitroandIn Vivo;Journal of Immunology Research;2014

3. The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human NeutrophilsIn Vitro;Mediators of Inflammation;2014

4. Signalling in Neutrophils: A Retro Look;ISRN Physiology;2013-11-07

5. Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?;Drug Design, Development and Therapy;2013-11